Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Giant cell tumors deriving from synovium are classified into a localized (GCT of tendon sheath; GCT-TS) and diffuse form (diffuse-type GCT, Dt-GCT). We propose a multidisciplinary management based upon a systematic review and authors' opinion. Open excision for GCT-TS and open synovectomy (plus excision) for Dt-GCT is advised to reduce the relatively high recurrence risk. External beam radiotherapy should be considered in severe cases, as Dt-GCT commonly extends extra-articular.

Original publication




Journal article


J surg oncol

Publication Date





433 - 445


Adult, Antineoplastic Agents, Arthroplasty, Arthroscopy, Benzamides, Chemotherapy, Adjuvant, Female, Giant Cell Tumors, Humans, Imatinib Mesylate, Indoles, Interdisciplinary Communication, Magnetic Resonance Imaging, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Piperazines, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Pyrimidines, Pyrroles, Radioisotopes, Radiotherapy, Adjuvant, Sunitinib, Synovectomy, Synovial Membrane, Tendons, Tenosynovitis